The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Purpose:A phase II–III randomised study to comparesafety and efficacy of an oxaliplatin/cyclophosphamide (OXAC)combination, vs. the reference combination of cisplatin/cyclophosphamide(CPC), in untreated advanced ovarian cancer patients. Patients and methods:182 patients were enrolled, of whom177 were treated; 86 with OXAC (130 mg/m2 oxaliplatintwo-hour intravenous (i.v.) infusion, 1000 mg/m2cyclophosphamide...
We report the case of an unresected, metastatic gastric cancer, which was treated with a very short course of the oral 5-fluorouracil (5-FU) prodrug S-1. The patient had to discontinue chemotherapy during the first treatment cycle due to severe toxicity, but achieved a pathologically confirmed, long-term complete response of her primary tumour, a diffuse-type poorly differentiated adenocarcinoma.
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.